


## Every day counts – identify MLD patients earlier

### Expediting diagnosis – 5 things to do

- Educate referral network to overcome “wait and see” mentality in the first line
- Symptomatic patients: expedited referral to an expert centre is critical
- Confirming MLD diagnosis early is essential for improved prognosis
- **Screen siblings of affected patients urgently to identify pre-symptomatic affected patients**
- Counselling on family planning for affected families



## Differential diagnosis: neurodevelopmental delay

### Other neurodegenerative diseases can mimic MLD<sup>7</sup>


- Elevated sulfatides or sulfatide accumulation
  - Multiple sulfatase deficiency (onset at 1–4 years, MLD-like clinical picture/Mucopolysaccharidosis-like features, very low ARSA enzyme activity)
  - Saposin B deficiency (variable onset: MLD-like clinical picture, ARSA enzyme activity in normal range)
- Progressive degenerative disorders that manifest after a period of normal development
  - Krabbe disease, x-linked adrenoleukodystrophy, Pelizaeus-Merzbacher disease, Alexander disease, Fucosidosis, Canavan disease, Gangliosidosis, Mucopolysaccharidoses
- Other genetic disorders where neuromotor delays may be a presenting feature
  - Angelman syndrome, Becker muscular dystrophy, Fragile X syndrome, Mitochondrial myopathies, Spinal muscular atrophy

#### References:

1. Kreysing J et al. Am. J. Hum. Genet 53:339–346, 1993. 2. Rosenberg JB et al. J Neurosci Res 2016;94(11):1169–79. 3. Zsolt et al. Acta Medica Marisiensis 2015;61(3):233–235. 4. Patil S, Maegawa GHB. Drug Des Devel Ther 2013;7:729–745. 5. Ferreira CR, Gahl WA. Transl Sci Rare Dis 2017;2(1–2):1–71. 6. Gieselmann V, Krägeloh-Mann I. Neuropediatrics 2010;41(1):1–6. 7. Lamichhane A, Rocha Cabrero F. Metachromatic Leukodystrophy. StatPearls Publishing; 2020 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560744> Accessed Feb 2021 8. Parikh et al. Molecular Genetics and Metabolism, 2015;501–515

© 2022 Orchard therapeutics. All Rights Reserved. IE-NoP-2200019 July 2022

layout: agentur.gestrichde · Druck: Darpe Industriedruck, darpe.de




## How to identify and diagnose MLD patients earlier and faster

Metachromatic Leukodystrophy (MLD) is a rare, fatal, inherited neurometabolic disease causing progressive demyelination and neurodegeneration.

IE-NoP-2200031 July 2022


 Orchard  
therapeutics™

# MLD causes progressive demyelination and neurodegeneration



Autosomal-recessive genetic disease caused by a deficiency of arylsulfatase A (ARSA) enzyme<sup>1-3</sup>

## Clinical course of MLD




Symptoms, age of onset and disease course vary, patients progress to dysphagia, severe neurological disability and death<sup>2,4-6</sup>

## Recognition of early symptoms of MLD

		LI-MLD	JU-MLD
First Signs		<30 months	30 months–16 years
<b>EARLY SYMPTOMS (selected)</b>			
Motor	Hypotonia	✓	
	Weakness	✓	
	Frequent falls	✓	
	Gait disturbances	✓	✓
	Abnormal movement patterns	✓	✓
Overall Development	Missing milestones	✓	✓
	General regression	✓	✓
Cognitive	Cognitive decline (school performance)		✓
	Speech difficulties		✓
	Behavioural changes (education problems)		✓
Trigger		<b>MOTOR</b>	<b>MOTOR / COGNITIVE</b>
Time to diagnosis		12 months	24 months

Early symptoms are difficult to recognise, missing developmental milestones and general regression should trigger further investigations<sup>7</sup>

## How to diagnose symptomatic MLD?



Blood ARSA levels should be used as a screening tool if milestones are missed or general regression occurs<sup>8</sup>